Phase 3 N=342 Preventing Health Disparities During Pregnancy Through Vitamin D Supplementation
Vitamin D3 Deficiency
Primary: Number of Participants With Greater Than 100 Nmol/L 25(OH)D (Converted Vitamin D) — 110; 22 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=151 Tinnitus Retraining Therapy Trial
Subjective Tinnitus
Primary: Change in Tinnitus Questionnaire (TQ) From Baseline to 3, 6, 12, and 18 Months — -17.8; -15.4; -11.5; -22.0 units on a scale — p=0.47
Phase 3 N=420 Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Open-Angle Glaucoma · Ocular Hypertension
Primary: Mean IOP — 19.17; 19.61; 18.46; 19.22 mm Hg — p=0.216
Phase 3 N=730 Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)
Diabetes Mellitus, Type 1
Primary: Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26 — 0.09; -0.44; -0.44 Percentage (%) — p=<0.0001
Phase 3 N=221 Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment
Mild Cognitive Impairment (MCI)
Primary: Number of Participants With a Decline of 6 Points on the Hopkins Verbal Learning Test-Revised (HVLT-R) — 1; 9 Participants — p=.02
Phase 3 N=300 Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe)
Fecal Incontinence
Primary: Change From Baseline St. Mark's (Vaizey) Score — -5.5; -4.4; -4.5; -3.4 units on a scale — p=0.092
Phase 3 N=5,060 Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS)
Cervical Intraepithelial Neoplasia
Primary: Percentage of Participants With Cervical Intraepithelial Neoplasia III (CIN III) — 10.93; 10.25; 10.84 percentage of participants
Phase 3 N=30 Efficacy of Rifaximin in Preventing Campylobacteriosis
Dysentery · Diarrhea · Enteric Campylobacteriosis
Primary: Campylobacteriosis — 13; 11 Participants
Phase 3 N=592 A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Primary: Progression-free Survival (PFS) According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) in Programmed…
Phase 3 N=336 Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone
Mycobacterium Infections, Nontuberculous
Primary: Number of Participants Achieving Culture Conversion by Month 6 in the Liposomal Amikacin for Inhalation (LAI) + Multi-drug Regimen (MDR) Arm Compared to the MDR Alone…
Phase 3 N=10,154 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)
Preeclampsia
Primary: Composite of Pregnancy-associated Hypertension and Serious Adverse Outcomes in the Mother or Fetus or Neonate — 305; 285 Participants — p=0.42
Phase 3 N=517 A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients
Gastroesophageal Reflux Disease
Primary: Rate of Non-recurrence at Week 52 — 44.8; 73.9; 55.2; 26.1 Percentage of participants — p=<0.001
Phase 3 N=1,918 Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy
Breast Cancer
Primary: Disease-free Survival (DFS) — 0.95; 0.91 probability of DFS at 5 years — p=0.01
Phase 3 N=31 Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients
Diabetes Mellitus, Type 1
Primary: Change in Plasma Glucose — 81.4; 84.2; 54.0 mg/dL — p=<0.001
Phase 3 N=41 Para-cervical Block Prior to Laparoscopic Hysterectomy as an Adjuvant Treatment to Reduce Postoperative Pain.
Pain, Postoperative
Primary: Pain Reported on the Visual Analogue Scale (VAS) at 30 Minutes Postoperative — 5.7; 3.2 VAS scale 0-10